Author Archives: Scalper1

Peak Oil And Runaway China: A Dangerous Combination Of Memes

By Ron Rimkus, CFA Back in 2005, investors heard an endless chorus in the financial media around two memes: the end of oil, and the growth of China. Oil production was supposedly hitting its upper limits. In 2005, the US Department of Energy published a study on the peaking of world oil production (.PDF) that stated: Because oil prices have been relatively high for the past decade, oil companies have conducted extensive exploration over that period, but their results have been disappointing [….] This is but one of a number of trends that suggest the world is fast approaching the inevitable peaking of conventional world oil production [….] The world has never faced a problem like this [….] Previous energy transitions (wood to coal and coal to oil) were gradual and evolutionary; oil peaking will be abrupt and revolutionary. The peak oil narrative was reaching a fever pitch around the same time as China’s “runaway growth” meme. A BBC report on ” 2004: China’s Coming Out Party ” highlighted how China’s increasing appetite for oil was affecting global prices. Other articles made eye-popping comparisons of China’s cities before and after the country’s economic changes (decades apart). For instance, Shenzhen transformed from a sleepy fishing village in 1980 to a bustling urban empire by 2006 . Shenzhen had grown at an annual pace of 28% per year during this 26-year period. Yes, you read that right. The pair of memes led some investors to embrace the notion that oil supply was peaking just at the moment that oil demand was accelerating- a recipe for higher and higher oil prices. Then, we all marveled as the price of oil rose from $30 per barrel in 2003 to well over $100 by 2008 . In subsequent years, both memes were proven wrong. There was no “abrupt and revolutionary” oil peaking, and China’s energy demands would not keep growing forever . But higher oil prices created an umbrella of opportunity for capital formation, and much of that capital flowed into US shale oil projects. Between 2009 and 2015, total US oil production nearly doubled from 5,000 barrels per day to just under 10,000 barrels per day , thanks largely to shale oil. The shale revolution, which took place because high prices stimulated investment and innovation, blew apart the notion that the world had reached peak oil. By the end of 2014, it became apparent that oil output would satisfactorily meet demand growth. Blindly following popular investment memes is a recipe for disaster, and investors who convinced themselves that oil prices would remain above $100 per barrel were blindsided by the return of oil priced under $40 per barrel – even though it was a function of price signals directing capital investment as a normal part of the business cycle. One person who correctly identified the business cycle as it played out was Amy Myers Jaffe , executive director for energy and sustainability at the University of California, Davis. “When I would talk about this boom and bust cycle in 2005 and 2007,” Jaffe said in a 2013 issue of The Planning Report , “people would heckle me off the stage because it looked like the price of oil was going to be high forever.” But time has a way of vindicating truth, and now her perspective looks quite prescient. Jaffe will be sharing her views on current events in global energy markets at the 69th CFA Institute Annual conference in Montréal. All posts are the opinion of the author. As such, they should not be construed as investment advice, nor do the opinions expressed necessarily reflect the views of CFA Institute or the author’s employer.

Nice Gouges Verint Systems Share On Emerging Market Shake-Up

Nice Systems ( NICE ) gouged Big Data cybersecurity rival  Verint Systems ‘ ( VRNT ) market share last year, with Nice’s share rising 2% as Verint’s enterprise business lost 12%, Deutsche Bank analyst Nandan Amladi wrote Wednesday. Amladi and Credit Suisse analyst Michael Nemeroff both downgraded Verint stock on Wednesday, after the company late Tuesday posted Q4 and 2016 results that missed expectations and gave 2017 guidance that also lagged views. Intraday on the stock market today , Verint stock plunged 12%, near 31. Nice stock was up a fraction in early afternoon trading Wednesday, near 65. For its fiscal Q4 ended Jan. 31, Verint reported $281.8 million in non-GAAP sales and 90 cents earnings per share ex items, down a respective 10% and 15% year over year. Both measures missed the consensus of seven analysts polled by Thomson Reuters for $318 million and $1.17. On the conference call Tuesday, Verint blamed macroeconomic weakness in emerging markets for the miss. For the year, non-GAAP sales fell 2% to $1.14 billion and EPS ex items fell 9% to $3.04. The consensus modeled $1.17 billion and $3.30. Amladi downgraded Verint stock to neutral from hold and cut his price target to 35 from 50. The emerging markets will continue slowing, and enterprise sales won’t be as strong as Verint suggests, he wrote in a research report. Late Tuesday, Verint guided to a 10%-15% decline in current-quarter security sales, slightly offset by mid- to high-single-digit enterprise sales growth. Fiscal 2017 sales, EPS and margins are expected to be flat. Amladi noted Verint is 50% exposed to the weak emerging-market segment, and that the company’s cyber intelligence head departed in February. Verint hasn’t seen a “blockbuster” deal since a $100 million accord in 2014, and current seven-figure deals are on the government side rather than enterprise, he said. Credit Suisse’s Nemeroff says investors could overlook Verint’s poor revenue guide if the company cut costs to leverage earnings, but adding that such a move “is not their strategy at this time.” Excluding a $150 million, two-year share buyback program — about 7% of Verint’s market cap — growth will stagnate in 2017 for the second year running, Nemeroff wrote in a report. He cut his price target to 29 from 45 and downgraded Verint stock to underperform from neutral. William Blair analyst Jonathan Ho, on the other hand, sees Verint recovering from its poor Q4, the third time in the past four quarters in which Verint either missed expectations or guided down. Investors should take advantage of the cheap valuation, he wrote in a report. “We believe the business should revert to normal,” he wrote. “However, we concede that there is a significant amount of macro uncertainty based on factors that could affect the timing of a rebound that are outside the company’s control.” Ho reiterated an outperform rating on Verint stock. Image provided by Shutterstock .

Intercept Pharma Gets Dueling Initiation Reports As FDA Panel Nears

Shares of biotech Intercept Pharmaceuticals ( ICPT ) were up in twice-average volume Wednesday, after two analysts launched coverage ahead of a crucial FDA panel vote. Credit Suisse’s Alethia Young initiated with a buy rating, while Salveen Richter at Goldman Sachs initiated with a neutral rating, though they agreed on the general outlines of the investment thesis. Intercept’s lead drug candidate, obeticholic acid (OCA), is up for an FDA advisory committee discussion on April 7 as a treatment for primary biliary cholangitis (PBC), a rare, chronic liver disease. If approved by the FDA’s May 29 deadline, it would be Intercept’s first commercial product. Young estimates that annual sales for obeticholic acid could hit $259 million in 2018, though Richter forecasts it at only $170 million at peak. Both analysts, however, agree that the really big potential market for OCA is in nonalcoholic steatohepatitis (NASH), a much more common liver disease without a current treatment. That could draw $3.5 billion a year, Richter estimates, but that’s a ways in the future: The next batch of data from the NASH clinical trial isn’t expected until 2018. Between the panel meeting and the NASH data, Richter sees “a dearth of catalysts” to drive Intercept’s stock, leading him to set his price target at 114. Young, however, says approval and launch for treatment of PBC, both in the U.S. and Europe, could provide more upside for the stock. Her peak sales estimate in NASH is almost twice Richter’s at $6.5 billion. She set her price target at 200. Intercept stock rose 5% in early trading on the stock market today , but by early afternoon it was up 1%, near 125.50. Shares hit a 19-month high above 314 last May.